Last reviewed · How we verify
XZP-3287 combined with rifampicin
XZP-3287 combined with rifampicin is a Small molecule drug developed by Xuanzhu Biopharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | XZP-3287 combined with rifampicin |
|---|---|
| Sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XZP-3287 combined with rifampicin CI brief — competitive landscape report
- XZP-3287 combined with rifampicin updates RSS · CI watch RSS
- Xuanzhu Biopharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about XZP-3287 combined with rifampicin
What is XZP-3287 combined with rifampicin?
XZP-3287 combined with rifampicin is a Small molecule drug developed by Xuanzhu Biopharmaceutical Co., Ltd..
Who makes XZP-3287 combined with rifampicin?
XZP-3287 combined with rifampicin is developed by Xuanzhu Biopharmaceutical Co., Ltd. (see full Xuanzhu Biopharmaceutical Co., Ltd. pipeline at /company/xuanzhu-biopharmaceutical-co-ltd).
What development phase is XZP-3287 combined with rifampicin in?
XZP-3287 combined with rifampicin is in Phase 1.
Related
- Manufacturer: Xuanzhu Biopharmaceutical Co., Ltd. — full pipeline